NasdaqGS:AMLXPharmaceuticals
Amylyx Pharmaceuticals (AMLX): A Valuation Check Following the Latest Equity Offering
Amylyx Pharmaceuticals (AMLX) is in the spotlight after completing a $175 million follow-on equity offering. For investors, these secondary offerings deserve close attention, since they can impact not only the share count but also the future direction of a company’s growth plans. In this case, Amylyx sold 17.5 million new shares at $10 each, slightly below its recent trading price, raising some questions about dilution and the company’s plans for its newly raised capital.
Over the past year,...